Exponent (EXPO) Q2 2024 earnings summary

Executive summary

• Net income grew 14% year-over-year in Q2 2024, with expanded EBITDA margin, despite moderated revenue growth due to headwinds in consumer electronics and chemicals and tough prior-year comparisons.

• Revenues for Q2 2024 were $140.5M, nearly flat year-over-year; revenues before reimbursements rose 2% to $132.4M, driven by demand for reactive services in transportation, utilities, and medical devices.

• Utilization improved to 75% from 69% year-over-year, despite a 9% decrease in technical FTEs.

• Strategic alignment of operating model and talent with market demand improved utilization and profitability.

• Company remains positioned for opportunities in life sciences, renewables, infrastructure, and transportation automation.

Financial highlights

• Q2 2024 total revenues were $140.5 million (flat year-over-year); net revenues increased 2% to $132.4 million.

• Net income rose to $29.2 million ($0.57 per diluted share) from $25.7 million ($0.50 per share) in Q2 2023.

• EBITDA increased 8% to $39.9 million (30.2% margin), up from $36.8 million (28.4% margin) in Q2 2023.

• Operating income for Q2 2024 was $35.7 million, up 19.6% year-over-year.

• Cash and cash equivalents increased to $203.3 million as of June 28, 2024.

Outlook and guidance

• Q3 2024 net revenues expected to be flat year-over-year; EBITDA margin guidance at 26.75%-27.5%.

• Full year 2024 net revenues expected to grow low- to mid-single digits; EBITDA margin 27.5%-28% (vs. 27.7% in 2023).

• Extra week in Q4 2024 to add ~5% to Q4 net revenues and 1.25% for the year.

• Utilization expected at 71%-73% in Q3 and 70.5%-72.5% for full year (vs. 69% in 2023).

• Management expects compensation and operating expenses to rise as new talent is added and investments in infrastructure continue.